GlassScriptPhysician profile
Hope A Hartig
NPI 1578168258
$1,345.78
in general payments reported to CMS, 2019-2025
34 companies · $581 in 2025
The $581 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.62 · 2022: $176 · 2023: $232 · 2024: $345 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,108 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,107.87 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $235.93 | 2025 | Freestyle Libre 3, Freestyle Insulinx |
| Dexcom, INC. | $178.86 | 2022-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $121.26 | 2022-2025 | Minimed 780g, Inceptiv, Minimed 770g |
| Cequr Corporation | $76.07 | 2023-2025 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $59.43 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novartis Pharmaceuticals Corporation | $54.55 | 2023-2024 | |
| Beta Bionics, INC. | $52.14 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Jazz Pharmaceuticals INC. | $42.24 | 2022-2024 | |
| Abiomed | $39.87 | 2025 | |
| Phathom Pharmaceuticals, INC. | $33.41 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $32.76 | 2024 | Nucala, Shingrix |
| Insulet Corporation | $31.43 | 2022-2025 | Omnipod |
| Amgen INC. | $30.32 | 2024-2025 | Otezla, Repatha, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $30.06 | 2022-2024 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.85 | 2024 | Jardiance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $22.77 | 2024 | Injectafer |
| Sequel Med Tech, LLC | $21.04 | 2025 | Twiist |
| Ascensia Diabetes Care US INC. | $19.80 | 2025 | |
| Sanofi-Aventis U.S. LLC | $17.66 | 2024 | |
| Aimmune Therapeutics, INC. | $16.31 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $16.26 | 2025 | Uptravi, Opsumit |
| Electromed, INC. | $15.76 | 2024 | Smartvest |
| Soleno Therapeutics, INC. | $15.70 | 2025 | Vykat Xr |
| Bayer Healthcare Pharmaceuticals INC. | $15.41 | 2022 | |
| Lundbeck LLC | $15.28 | 2024 | Vyepti |
| Pfizer INC. | $15.27 | 2022 | |
| Aurinia Pharma U.S., INC. | $15.19 | 2024 | Lupkynis |
| Collegium Pharmaceutical, INC. | $15.01 | 2025 | Belbuca |
| Calliditas Therapeutics US INC. | $14.71 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.61 | 2024 | Jynarque |
| Rgh Enterprises LLC | $14.00 | 2024 | |
| Lilly USA, LLC | $13.57 | 2023 | |
| Ardelyx, INC. | $13.29 | 2024 | Ibsrela |
| Kowa Pharmaceuticals America, INC. | $12.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hope Hartig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.